Ask AI
MF/SS: Systemic Therapy

CME

New Systemic Therapies for Mycosis Fungoides and Sézary Syndrome

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: March 05, 2020

Expiration: March 04, 2021

Activity

Progress
1
Course Completed

In this module, Francine Foss, MD, provides an overview of the diagnosis and treatment of patients with mycosis fungoides (MF) or Sézary syndrome (SS), with a focus on the most recently approved systemic therapies.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset; they can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once before the discussion that informs the best choice and then again after that specific discussion. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing clinician, how many patients with MF or SS do you see in an average year?
In your current practice, which of the following treatment options would you recommend for this patient?
In your current practice, which of the following treatment options would you recommend for this patient?
Which of the following is the target of mogamulizumab?